The modest alcohol consumption reduces the incidence of fatty liver in men: A population-based large-scale cohort study

Journal of Gastroenterology and Hepatology (Australia)

Volumn 30, Issue 3, 2015, Pages 546-552

  Hashimoto, Yoshitaka ^a   Hamaguchi, Masahide ^a   Kojima, Takao ^b   Ohshima, Yasuhiro ^b   Ohbora, Akihiro ^b   Kato, Takahiro ^b   Nakamura, Naoto ^a   Fukui, Michiaki ^a  

^a KYOTO PREFECTURAL UNIVERSITY OF MEDICINE   (Japan)

^b ASAHI UNIVERSITY   (Japan)

Author keywords

Epidemiology; Fatty liver; NAFLD; Obesity

Indexed keywords

ADULT; ALCOHOL CONSUMPTION; ARTICLE; COHORT ANALYSIS; FATTY LIVER; FEMALE; HUMAN; JAPANESE (PEOPLE); LIFESTYLE; LONGITUDINAL STUDY; MAJOR CLINICAL STUDY; MALE; MEDICAL HISTORY; POPULATION RESEARCH; PRIORITY JOURNAL; QUESTIONNAIRE; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS; DRINKING BEHAVIOR; ECHOGRAPHY; INCIDENCE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; SEXUAL DEVELOPMENT;

ADULT; ALCOHOL DRINKING; ASIAN CONTINENTAL ANCESTRY GROUP; BODY MASS INDEX; COHORT STUDIES; FATTY LIVER; HUMANS; INCIDENCE; LIFE STYLE; MALE; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; QUESTIONNAIRES; SEX CHARACTERISTICS;

EID: 84923264318     PISSN: 08159319     EISSN: 14401746     Source Type: Journal    
DOI: 10.1111/jgh.12786     Document Type: Article

References (44)

1. Angulo P. Nonalcoholic fatty liver disease. N. Engl. J. Med. 2002; 346: 1221-1231.
2. Neuschwander-Tetri BA, Caldwell SH. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003; 37: 1202-1219.
3. Ioannou GN, Weiss NS, Boyko EJ, Mozaffarian D, Lee SP. Elevated serum alanine aminotransferase activity and calculated risk of coronary heart disease in the United States. Hepatology 2006; 43: 1145-1151.
4. Hamaguchi M, Kojima T, Takeda N etal. The metabolic syndrome as a predictor of nonalcoholic fatty liver disease. Ann. Intern. Med. 2005; 143: 722-728.
5. Harrison SA, Day CP. Benefits of lifestyle modification in NAFLD. Gut 2007; 56: 1760-1769.
6. Centis E, Marzocchi R, Di Domizio S, Ciaravella MF, Marchesini G. The effect of lifestyle changes in non-alcoholic fatty liver disease. Dig. Dis. 2010; 28: 267-273.
7. Siler SQ, Neese RA, Hellerstein MK. De novo lipogenesis, lipid kinetics, and whole-body lipid balances in humans after acute alcohol consumption. Am. J. Clin. Nutr. 1999; 70: 928-936.
8. Wong VW-S, Chu WC-W, Wong GL-H etal. Prevalence of non-alcoholic fatty liver disease and advanced fibrosis in Hong Kong Chinese: a population study using proton-magnetic resonance spectroscopy and transient elastography. Gut 2012; 61: 409-415.
9. Bellentani S, Saccoccio G, Costa G etal. Drinking habits as cofactors of risk for alcohol induced liver damage. The Dionysos Study Group. Gut 1997; 41: 845-850.
10. Bedogni G, Miglioli L, Masutti F etal. Incidence and natural course of fatty liver in the general population: the Dionysos study. Hepatology 2007; 46: 1387-1391.
11. Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Protective effect of alcohol consumption for fatty liver but not metabolic syndrome. World J. Gastroenterol. 2012; 18: 156-167.
12. Gunji T, Matsuhashi N, Sato H etal. Light and moderate alcohol consumption significantly reduces the prevalence of fatty liver in the Japanese male population. Am. J. Gastroenterol. 2009; 104: 2189-2195.
13. Sookoian S, Castaño GO, Pirola CJ. Modest alcohol consumption decreases the risk of non-alcoholic fatty liver disease: a meta-analysis of 43175 individuals. Gut 2013; 63: 530-532.
14. Hamaguchi M, Kojima T. Favorable effect of modest alcohol consumption to fatty liver disease. World J. Gastroenterol. 2013; 19: 5393-5394.
15. Liangpunsakul S, Chalasani N. What should we recommend to our patients with NAFLD regarding alcohol use? Am. J. Gastroenterol. 2012; 107: 976-978.
16. Suzuki A, Angulo P, St Sauver J, Muto A, Okada T, Lindor K. Light to moderate alcohol consumption is associated with lower frequency of hypertransaminasemia. Am. J. Gastroenterol. 2007; 102: 1912-1919.
17. Ruhl CE, Everhart JE. Joint effects of body weight and alcohol on elevated serum alanine aminotransferase in the United States population. Clin. Gastroenterol. Hepatol. 2005; 3: 1260-1268.
18. Hamaguchi M, Kojima T, Itoh Y etal. The severity of ultrasonographic findings in nonalcoholic fatty liver disease reflects the metabolic syndrome and visceral fat accumulation. Am. J. Gastroenterol. 2007; 102: 2708-2715.
19. McCullough AJ. The clinical features, diagnosis and natural history of nonalcoholic fatty liver disease. Clin. Liver Dis. 2004; 8: 521-533.
20. Aaron DJ, Kriska AM, Dearwater SR, Cauley JA, Metz KF, LaPorte RE. Reproducibility and validity of an epidemiologic questionnaire to assess past year physical activity in adolescents. Am. J. Epidemiol. 1995; 142: 191-201.
21. Ryu S, Chang Y, Kim D-I, Kim WS, Suh BS. gamma-Glutamyltransferase as a predictor of chronic kidney disease in nonhypertensive and nondiabetic Korean men. Clin. Chem. 2007; 53: 71-77.
22. Moriya A, Iwasaki Y, Ohguchi S etal. Alcohol consumption appears to protect against non-alcoholic fatty liver disease. Aliment. Pharmacol. Ther. 2011; 33: 378-388.
23. Dunn W, Sanyal AJ, Brunt EM etal. Modest alcohol consumption is associated with decreased prevalence of steatohepatitis in patients with non-alcoholic fatty liver disease (NAFLD). J. Hepatol. 2012; 57: 384-391.
24. Howard AA, Arnsten JH, Gourevitch MN. Effect of alcohol consumption on diabetes mellitus: a systematic review. Ann. Intern. Med. 2004; 140: 211-219.
25. Koppes LLJ, Dekker JM, Hendriks HFJ, Bouter LM, Heine RJ. Moderate alcohol consumption lowers the risk of type 2 diabetes: a meta-analysis of prospective observational studies. Diabetes Care 2005; 28: 719-725.
26. Ronksley PE, Brien SE, Turner BJ, Mukamal KJ, Ghali WA. Association of alcohol consumption with selected cardiovascular disease outcomes: a systematic review and meta-analysis. BMJ 2011; 342: d671.
27. Agarwal DP. Cardioprotective effects of light-moderate consumption of alcohol: a review of putative mechanisms. Alcohol Alcohol. 2002; 37: 409-415.
28. Fukui M, Kitagawa Y, Nakamura N, Kadono M, Hasegawa G, Yoshikawa T. Association between alcohol consumption and serum dehydroepiandrosterone sulphate concentration in men with Type 2 diabetes: a link to decreased cardiovascular risk. Diabet. Med. 2005; 22: 1446-1450.
29. Senmaru T, Fukui M, Okada H etal. Testosterone deficiency induces markedly decreased serum triglycerides, increased small dense LDL, and hepatic steatosis mediated by dysregulation of lipid assembly and secretion in mice fed a high-fat diet. Metabolism 2013; 62: 851-860.
30. Méndez-Sánchez N, Arrese M, Zamora-Valdés D, Uribe M. Current concepts in the pathogenesis of nonalcoholic fatty liver disease. Liver Int. 2007; 27: 423-433.
31. Yamauchi T, Kamon J, Minokoshi Y etal. Adiponectin stimulates glucose utilization and fatty-acid oxidation by activating AMP-activated protein kinase. Nat. Med. 2002; 8: 1288-1295.
32. Sierksma A, Patel H, Ouchi N etal. Effect of moderate alcohol consumption on adiponectin, tumor necrosis factor-alpha, and insulin sensitivity. Diabetes Care 2004; 27: 184-189.
33. Pischon T, Girman CJ, Rifai N, Hotamisligil GS, Rimm EB. Association between dietary factors and plasma adiponectin concentrations in men. Am. J. Clin. Nutr. 2005; 81: 780-786.
34. Nakajima T, Kamijo Y, Tanaka N etal. Peroxisome proliferator-activated receptor alpha protects against alcohol-induced liver damage. Hepatology 2004; 40: 972-980.
35. Nishiyama Y, Goda N, Kanai M etal. HIF-1α induction suppresses excessive lipid accumulation in alcoholic fatty liver in mice. J. Hepatol. 2012; 56: 441-447.
36. Hashimoto E, Tokushige K. Prevalence, gender, ethnic variations, and prognosis of NASH. J. Gastroenterol. 2011; 46 (Suppl. 1): 63-69.
37. Omagari K, Kadokawa Y, Masuda J etal. Fatty liver in non-alcoholic non-overweight Japanese adults: incidence and clinical characteristics. J. Gastroenterol. Hepatol. 2002; 17: 1098-1105.
38. Gutierrez-Grobe Y, Ponciano-Rodríguez G, Ramos MH, Uribe M, Méndez-Sánchez N. Prevalence of non alcoholic fatty liver disease in premenopausal, postmenopausal and polycystic ovary syndrome women. The role of estrogens. Ann. Hepatol. 2010; 9: 402-409.
39. Shimizu I, Kohno N, Tamaki K etal. Female hepatology: favorable role of estrogen in chronic liver disease with hepatitis B virus infection. World J. Gastroenterol. 2007; 13: 4295-4305.
40. Hamaguchi M, Kojima T, Ohbora A, Takeda N, Fukui M, Kato T. Aging is a risk factor of nonalcoholic fatty liver disease in premenopausal women. World J. Gastroenterol. 2012; 18: 237-243.
41. Frezza M, di Padova C, Pozzato G, Terpin M, Baraona E, Lieber CS. High blood alcohol levels in women. The role of decreased gastric alcohol dehydrogenase activity and first-pass metabolism. N. Engl. J. Med. 1990; 322: 95-99.
42. Becker U, Deis A, Sørensen TI etal. Prediction of risk of liver disease by alcohol intake, sex, and age: a prospective population study. Hepatology 1996; 23: 1025-1029.
43. Hernaez R, Lazo M, Bonekamp S etal. Diagnostic accuracy and reliability of ultrasonography for the detection of fatty liver: a meta-analysis. Hepatology 2011; 54: 1082-1090.
44. Ekstedt M, Franzén LE, Holmqvist M etal. Alcohol consumption is associated with progression of hepatic fibrosis in non-alcoholic fatty liver disease. Scand. J. Gastroenterol. 2009; 44: 366-374.